Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome.
10.1007/s11655-024-3818-1
- Author:
Yang CHENG
1
,
2
;
Hao-Yi WANG
3
;
Cheng-Yi WAN
3
;
Jie-Wen SHI
3
;
Yuan-Yuan JIN
3
;
Sheng-Li HE
4
;
Bao-Bing YIN
5
;
Jian-Jie CHEN
3
Author Information
1. Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. drchengyang@
2. com.
3. Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
4. Department of Oncology, Minhang Branch of Tumor Hospital Affiliated to Fudan University, Shanghai, 200240, China.
5. Department of General Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai, 200040, China.
- Publication Type:Randomized Controlled Trial
- Keywords:
Erzhu Jiedu Decoction Granules;
Pi (Spleens-deficiency and dampness-heat syndrome;
hepatitis B virus-associated primary liver cancer
- MeSH:
Humans;
Drugs, Chinese Herbal/adverse effects*;
Male;
Female;
Middle Aged;
Liver Neoplasms/complications*;
Hepatitis B virus/physiology*;
Hepatitis B/complications*;
Treatment Outcome;
Adult;
Spleen/drug effects*;
Quality of Life;
Medicine, Chinese Traditional;
Aged;
Syndrome
- From:
Chinese journal of integrative medicine
2025;31(5):394-401
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To assess the efficacy and safety of Erzhu Jiedu Decoction (EZJDD) Granules in treating mid-advanced hepatitis B virus-associated primary liver cancer (HBV-PLC) patients with Pi (Spleen)-deficiency and dampness-heat syndrome.
METHODS:From January 2021 to June 2023, a cohort of 132 patients were enrolled and randomly assigned to a control group or a EZJDD group according to the random numbers, with 66 patients in each group. The patients in the control group received conventional treatment for 3 months, followed by a 3-month follow-up. In addition to the conventional treatment, patients in the EZJDD group were administered EZJDD Granules (10.9 g/pack, 2 packs twice per day) orally for same duration. Progression-free survival (PFS) as primary outcome was evaluated by Kaplan Meier method. Karnofsky performance status (KPS) scores were used to assess the quality of life in two groups before and after treatment, and survival rates were determined as well. The efficacy of Chinese medicine syndrome was calculated with Nimodipine method. Liver function, tumor indicators and T lymphocyte subsets were measured, respectively. Safety indicators were recorded and assessed.
RESULTS:Of the 116 patients who completed the study, 57 were in the control group and 59 in the EZJDD group. The median PFS was 3.53 months (106 days) in the EZJDD group compared to 2.33 months (70 days) in the control group (P=0.005). Six-month survival rate was 52.63% (30/57) in the control group and 69.49% (41/59) in the EZJDD group (P=0.039). The median KPS score in the EZJDD group [70(63, 90)] was higher than that in the control group [70(60, 80)] (P=0.013). The total effective rate of CM syndrome was 52.63% (30/57) in the control group and 77.97% (46/59) in the EZJDD group (P=0.005). The levels of alpha fetoprotein, alpha fetoprotein-L3, alpha-L-fucosidase and protein induced by Vitamin K absence or antagonist- II in the EZJDD group increased less than the control group (P>0.05). CD8+ levels were decreased, while CD3+ and CD4+ levels, as well as CD4+/CD8+ ratio were significantly increased in the EZZJD group (P<0.05). No treatment-related adverse reactions were observed during the study.
CONCLUSION:EZJDD Granules significantly prolonged the median PFS and improved 6-month survival rate in patients with mid-advanced HBV-PLC (Registration No. ChiCTR2200056922).
